Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA

The Journal of clinical endocrinology and metabolism6 Sept 2005Cited by 221 (Europe PMC)

PMID16144950DOI10.1210/jc.2005-1093PepBankPUB-16144950

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, exenatide restored the first-phase insulin secretory pattern in contrast to saline-treated diabetic subjects.
In plain wordsExenatide restored early insulin release in patients with type 2 diabetes compared with saline-treated diabetic patients.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseFirst-phase insulin secretion versus diabetic saline group
Study
n = 13
Comparator
Saline-treated type 2 diabetes subjects
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Exenatide-treated DM2 subjects had an insulin secretory pattern similar to healthy subjects in both first (0-10 min) and second (10-180 min) phases after glucose challenge, in contrast to saline-treated DM2 subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
DM2 subjects administered saline had diminished first-phase insulin secretion, compared with healthy control subjects.
Summary · context
Subjects received iv exenatide (DM2) or saline (DM2 and healthy volunteers), followed by iv glucose challenge.
Summary · context
Thirteen evaluable DM2 subjects were included in the study: 11 males, two females; age, 56 +/- 7 yr; body mass index, 31.7 +/- 2.4 kg/m2; hemoglobin A1c, 6.6 +/- 0.7% (mean +/- sd) treated with diet/exercise (n = 1), metformin (n = 10), or acarbose (n = 2).
Report a problemFND-1614495001
02HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, exenatide produced a healthy-like second-phase insulin secretory pattern in contrast to saline-treated diabetic subjects.
In plain wordsExenatide produced a more normal later insulin-release pattern compared with saline-treated diabetic patients.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSecond-phase insulin secretion versus diabetic saline group
Study
n = 13
Comparator
Saline-treated type 2 diabetes subjects
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Exenatide-treated DM2 subjects had an insulin secretory pattern similar to healthy subjects in both first (0-10 min) and second (10-180 min) phases after glucose challenge, in contrast to saline-treated DM2 subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received iv exenatide (DM2) or saline (DM2 and healthy volunteers), followed by iv glucose challenge.
Summary · context
Thirteen evaluable DM2 subjects were included in the study: 11 males, two females; age, 56 +/- 7 yr; body mass index, 31.7 +/- 2.4 kg/m2; hemoglobin A1c, 6.6 +/- 0.7% (mean +/- sd) treated with diet/exercise (n = 1), metformin (n = 10), or acarbose (n = 2).
Report a problemFND-1614495002
03HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, exenatide-treated subjects had a first-phase insulin secretory pattern similar to healthy subjects.
In plain wordsEarly insulin release in exenatide-treated diabetic patients resembled that in healthy subjects.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFirst-phase insulin secretion versus healthy subjects
Study
n = 13
Comparator
Healthy subjects
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Exenatide-treated DM2 subjects had an insulin secretory pattern similar to healthy subjects in both first (0-10 min) and second (10-180 min) phases after glucose challenge, in contrast to saline-treated DM2 subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received iv exenatide (DM2) or saline (DM2 and healthy volunteers), followed by iv glucose challenge.
Summary · context
Thirteen evaluable DM2 subjects were included in the study: 11 males, two females; age, 56 +/- 7 yr; body mass index, 31.7 +/- 2.4 kg/m2; hemoglobin A1c, 6.6 +/- 0.7% (mean +/- sd) treated with diet/exercise (n = 1), metformin (n = 10), or acarbose (n = 2).
Report a problemFND-1614495003
04HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, exenatide-treated subjects had a second-phase insulin secretory pattern similar to healthy subjects.
In plain wordsLater insulin release in exenatide-treated diabetic patients resembled that in healthy subjects.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSecond-phase insulin secretion versus healthy subjects
Study
n = 13
Comparator
Healthy subjects
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Exenatide-treated DM2 subjects had an insulin secretory pattern similar to healthy subjects in both first (0-10 min) and second (10-180 min) phases after glucose challenge, in contrast to saline-treated DM2 subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received iv exenatide (DM2) or saline (DM2 and healthy volunteers), followed by iv glucose challenge.
Summary · context
Thirteen evaluable DM2 subjects were included in the study: 11 males, two females; age, 56 +/- 7 yr; body mass index, 31.7 +/- 2.4 kg/m2; hemoglobin A1c, 6.6 +/- 0.7% (mean +/- sd) treated with diet/exercise (n = 1), metformin (n = 10), or acarbose (n = 2).
Report a problemFND-1614495004
05HumanNon-randomized trialSafety outcome
In type 2 diabetes, moderate nausea occurred in two of 13 exenatide-treated subjects and was the most common adverse event.
In plain wordsModerate nausea affected two of 13 exenatide-treated patients and was the most common adverse event.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableModerate nausea
Study
n = 13
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · intravenousAs given in this study (human).
Measurements
Subjects with moderate nausea
2 subjects
of 13 exenatide-treated DM2 subjects
Source sentences
Summary
In exenatide-treated DM2 subjects, the most common adverse event was moderate nausea (two of 13 subjects).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received iv exenatide (DM2) or saline (DM2 and healthy volunteers), followed by iv glucose challenge.
Summary · context
Thirteen evaluable DM2 subjects were included in the study: 11 males, two females; age, 56 +/- 7 yr; body mass index, 31.7 +/- 2.4 kg/m2; hemoglobin A1c, 6.6 +/- 0.7% (mean +/- sd) treated with diet/exercise (n = 1), metformin (n = 10), or acarbose (n = 2).
Report a problemFND-1614495005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.